Novaminsulfon 500 (Metamizole Sodium Monohydrate)

Metamizole sodium, the active ingredient in Novaminsulfon 500, is a pyrazolone analgesic presented as a 500 mg oral tablet for systemic use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients, particularly when other analgesics are insufficient or not tolerated.

GNH USA supplies Novaminsulfon 500 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing EU‑sourced product quality and regulatory compliance while ensuring consistent batch release and supporting global distribution networks.

Novaminsulfon (metamizole sodium) is used in the management of pain and fever across several clinical situations. - Pain: provides analgesic relief for moderate to severe acute pain. - Fever: reduces elevated body temperature in febrile conditions. - Post‑operative pain: controls pain after surgical procedures. - Cancer‑related pain: helps manage breakthrough pain when other agents are inadequate.

Metamizole sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Vomiting: occasional episodes. - Dizziness: transient light‑headedness. - Headache: mild tension‑type pain. - Skin rash: mild erythema or pruritus.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Anaphylactic reaction: acute hypersensitivity with airway compromise. - Stevens‑Johnson syndrome: severe mucocutaneous eruption. - Hepatic dysfunction: elevated liver enzymes indicating liver injury. - Severe hypotension: sudden drop in blood pressure requiring medical intervention.

When prescribing Metamizole sodium, clinicians should consider several safety precautions to minimize risk. - Renal impairment: adjust use in patients with reduced kidney function. - Hepatic disease: avoid or monitor in liver dysfunction. - History of blood dyscrasias: contraindicated in prior agranulocytosis. - Concomitant immunosuppressants: increased infection risk. - Pregnancy and lactation: use only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and direct sunlight.

Metamizole sodium can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticoagulants: may enhance bleeding risk. - Cyclosporine: increased risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: additive gastrointestinal irritation. - Lithium: may increase serum lithium levels. - Methotrexate: possible enhanced toxicity. - ACE inhibitors: potential for reduced renal function.